Adam Rupert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adam Rupert has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Irini Sereti
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland
2 shared publications Ajantha Rhodes
Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia; Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia
1 shared publication- Alexandra M. Ortiz
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
1 shared publication - Alexandra Schuetz
US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
1 shared publication - Brian Ingram
Metabolon, Morrisville, NC
1 shared publication - Claire Deleage
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (9)
Corrigendum to: Impact of Acute HIV Infection and Early Antiretroviral Therapy on the Human Gut Microbiome
Open Forum Infectious Diseases, ofz367, https://doi.org/10.1093/ofid/ofz367
- 1 September 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (9)
Open AccessCorrigendum to: Impact of Acute HIV Infection and Early Antiretroviral Therapy on the Human Gut Microbiome
Open Forum Infectious Diseases, ofz367, https://doi.org/10.1093/ofid/ofz367
- Open Access
- 11 July 2017
- Published by Case Western Reserve University in Pathogens and Immunity
- Vol. 2 (3) , 310-334
A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals
Background: In HIV infection, lymphoid tissue is disrupted by fibrosis. Angiotensin converting enzyme inhibitors have anti-fibrotic properties. We completed a pilot study to assess whether the addition of lisinopril to antiretroviral therapy (ART) reverses fibrosis of gut tissue, and whether this leads to reduction of HIV RNA and DNA levels.Methods: Thirty HIV-infected individuals on ART were randomized to lisinopril at 20mg daily or matching placebo for 24 weeks. All participants underwent rectal biopsies prior to starting the study drug and at 22 weeks, and there were regular blood draws. The primary end point was the change in HIV RNA and DNA levels in rectal tissue. Secondary outcomes included the change in 1) HIV levels in blood; 2) Gag-specific T-cell responses; 3) levels of T-cell activation; and 4) collagen deposition.Results: The addition of lisinopril did not have a significant effect on the levels of HIV RNA or DNA in gut tissue or blood, Gag-specific responses, or levels of T-cell activation. Lisinopril also did not have a significant impact on lymphoid fibrosis in the rectum, as assessed by quantitative histology or heavy water labeling.Conclusions: Treatment with lisinopril for 24 weeks in HIV-infected adults did not have an effect on lymphoid fibrosis, immune activation, or gut tissue viral reservoirs. Further study is needed to see if other anti-fibrotic agents may be useful in reversing lymphoid fibrosis and reducing HIV levels.Clinical Trials Registration: NCT01535235
- 11 July 2017
- Published by Case Western Reserve University in Pathogens and Immunity
- Vol. 2 (3) , 310-334
Open AccessA Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals
Background: In HIV infection, lymphoid tissue is disrupted by fibrosis. Angiotensin converting enzyme inhibitors have anti-fibrotic properties. We completed a pilot study to assess whether the addition of lisinopril to antiretroviral therapy (ART) reverses fibrosis of gut tissue, and whether this leads to reduction of HIV RNA and DNA levels.Methods: Thirty HIV-infected individuals on ART were randomized to lisinopril at 20mg daily or matching placebo for 24 weeks. All participants underwent rectal biopsies prior to starting the study drug and at 22 weeks, and there were regular blood draws. The primary end point was the change in HIV RNA and DNA levels in rectal tissue. Secondary outcomes included the change in 1) HIV levels in blood; 2) Gag-specific T-cell responses; 3) levels of T-cell activation; and 4) collagen deposition.Results: The addition of lisinopril did not have a significant effect on the levels of HIV RNA or DNA in gut tissue or blood, Gag-specific responses, or levels of T-cell activation. Lisinopril also did not have a significant impact on lymphoid fibrosis in the rectum, as assessed by quantitative histology or heavy water labeling.Conclusions: Treatment with lisinopril for 24 weeks in HIV-infected adults did not have an effect on lymphoid fibrosis, immune activation, or gut tissue viral reservoirs. Further study is needed to see if other anti-fibrotic agents may be useful in reversing lymphoid fibrosis and reducing HIV levels.Clinical Trials Registration: NCT01535235